Enterome, a clinical-stage biotech company developing innovative therapies to treat microbiome-associated diseases with a focus on auto-immune disease and cancer, has entered...

LNC aims to develop the first Christensenella-based drug candidate for the treatment of obesity and metabolic disorders

Vedanta Biosciences, a clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally defined consortia of human...

LNC Therapeutics, a French biotech company specialized in the gut microbiome-based drug discovery,has announced the launch of a new clinical trial with Stablor®, OBEMINALE 2,...

A-Mansia Biotech S.A., a belgian microbiome company, announces a €13 million first close of its Series A financing, led by Seventure Partners.

MaaT Pharma, a clinical-stage biopharmaceutical company, received authorization from competent authorities to launch its phase II prospective multicenter clinical trial in...

Zipongo plans to use the additional funding to expand its nutrition platform beyond wellness to use food as first-line therapy in treating chronic disease.

VE303 is first known rationally-defined bacterial consortium in powder form to enter the clinic and has recieved Orphan Drug designation from the US FDA for C. difficile...

New collaborations with Leiden University Medical Center and the Mitchell Cancer Institute focused on melanoma and cancers of the bladder, head and neck, and kidneys